Alpha-emitter PRRT: Phase 1/2 Study of AlphaMedix™ in Adult Subjects With SSTR positive NET

Ebrahim S Delpassand, Izabela Tworowska, Rouzbeh Esfandiari, Julien Torgue, Jason Hurt, Afshin Shafie and Rodolfo Núñez Journal of Nuclear Medicine, January 2022, jnumed.121.263230; DOI: https://doi.org/10.2967/jnumed.121.263230
Translate

Trial Summary

AlphaMedix™ (²¹²Pb-DOTAMTATE) is a radiotherapeutic drug indicated in subjects with unresectable, metastatic somatostatin receptor (SSTR) positive neuroendocrine tumors (NETs). Because 212Pb is an in vivo generator of alpha particles, it is particularly suitable for SSTR therapy applications, i.e. it’s a type of PRRT. 

This drug addresses an unmet need in the field of peptide receptor radionuclide therapy (PRRT) for NETs. Substitution of an alpha emitter (²¹²Pb) for the beta emitters currently being used (i.e., 177Lu or 90Y) will provide significantly higher Linear Energy Transfer (LET) and a shorter path length. Higher LET particles should cause more tumor cell death. A shorter path length should result in less collateral damage to the normal tissue and therefore fewer side effects for subjects receiving the drug.

The phase 1 trial completed in July 2022 and we await news on any early Phase 2 data.

A Phase 2 Open Label Study to Evaluate the Safety and Effectiveness of 212Pb-DOTAMTATE in PRRT Naive Subjects With Somatostatin Receptor Expressing Neuroendocrine Tumors. 

Actual Study Start Date :December 21, 2021
Estimated Primary Completion Date :December 1, 2022
Estimated Study Completion Date :December 1, 2023

Read more detail about the phase 2 trial announcement by clicking here

Source: Targeted Alpha-Emitter Therapy With 212Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Human, Dose-Escalation Clinical Trial

Ebrahim S DelpassandIzabela TworowskaRouzbeh EsfandiariJulien TorgueJason HurtAfshin Shafie and Rodolfo Núñez

The source document above includes a picture of one patient from Phase 1 who appears to have had a great response (a lung NET) but remember, this may not be the same response in all participants. 

Ebrahim S Delpassand, Izabela Tworowska, Rouzbeh Esfandiari, Julien Torgue, Jason Hurt, Afshin Shafie and Rodolfo Núñez Journal of Nuclear Medicine, January 2022, jnumed.121.263230; DOI: https://doi.org/10.2967/jnumed.121.263230

Read more here

1.  Phase 1 ClinicalTrials.gov Identifier:  NCT03466216
2.  Phase 2 ClinicalTrials.gov Identifier: NCT05153772
3.  Targeted Alpha Therapy (PRRT) blog post – click here

Click on the picture to read more

General Clinical Trials Disclaimer

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided in the clinical trials document. It’s very important to check the trial inclusion and exclusion criteria before making any contact.  If you need questions, the articles here is very useful Questions to Ask About Clinical Trials | Cancer.Net

The inclusion of any trial within this blog should not be taken as a recommendation by Ronny Allan. 

 
 

Disclaimer

I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.  Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional as they are not members of the private group or followers of my sites in any official capacity.  Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.

Finally

Whenever I post about a trial or study, some people get excited without understanding that these new treatments and capabilities can very often take years to come to fruition and it’s also possible that clinical trials can be halted, or that national approval agencies will not approve the final product.  Plus, not everyone will be eligible, so always check the exclusion and inclusion criteria in the relevant clinical trials document  Please bear that in mind when reading studies/clinical trials posted on RonnyAllan.NET

Subscribe to my newsletter

Thanks for reading.

Ronny

I’m also active on Facebook. Like my page for even more news. Help me build up my new site here – click here and ‘Like’

Sign up for my newsletters – Click Here

Disclaimer

My Diagnosis and Treatment History

Follow me on twitter

Check out my online presentations

Check out my WEGO Health Awards

Like my new awareness page – click here or on the photo.  (Like rather than follow please!)

Check out my Glossary of Terms – click here

patients included

Please Share this post for Neuroendocrine Cancer awareness and to help another patient

 
 
 
Facebook
Twitter
Pinterest
WhatsApp
Email

Lanreotide: 12 more years

I once wrote a blog entitled “Four more years“.  I was watching the US elections back in 2014/15 and that phrase come up after it

Read More »

RonnyAllan.NET – Summary of November 2022

In November 2022, I was very active on my blog site as it was World Neuroendocrine Cancer Day on 10th Nov (although every day is

Read More »

In the news – new Neuroendocrine Tumour PET Fluorine-18 based ‘tracer’

This should be of interest, particularly to Canadians. (Not to be confused with 18F-FDG which is a different scan). For people waiting for imaging tests

Read More »

Incurable isn’t terminal

Opinion Words are important I was diagnosed with stage IV cancer in 2010.  OK, it wasn’t a really aggressive type but it had caused a

Read More »

The Inspirational Wilko Johnson: 12 July 1947 – 21 November 2022

Wilko playing at his last show. Oct 2022 in London. Aged 75. RIP Wilko Johnson – Neuroendocrine Cancer I have been following Wilko’s cancer story

Read More »

Neuroendocrine Neoplasms (NEN) – genetic related syndromes

Definitions – the differences between Hereditary vs Familial vs Genetic Disorders I wanted to start with these definitions because people may unintentionally use these three

Read More »

Neuroendocrine Cancer: Those who know, know!

Over the years of my advocating, I’ve tried to explain Neuroendocrine Cancer to many people outside the community.  Some ‘get it’ but many don’t.  Most

Read More »

Ask More, Assume Less

This is a great catchphrase from Neuroendocrine Cancer UK. It is partly based on the realisation that Neuroendocrine Cancer is no longer rare.  OK, that

Read More »

Piss off Cancer, it’s been 12 years since my “big surgery”

I’m still here I was 54 years and 9 months old at diagnosis on 26th July 2010.  For the first few months, I had no

Read More »

One thought on “Alpha-emitter PRRT: Phase 1/2 Study of AlphaMedix™ in Adult Subjects With SSTR positive NET

I love comments - feel free!

%d bloggers like this: